Impact of dose reduction on survival in patients starting sunitinib (SU) or pazopanib (PA) as first-line for metastatic renal cell carcinoma (mRCC).

被引：0
|
作者：
Iacovelli, Roberto
Derosa, Lisa
Massari, Francesco
Verri, Elena
Galli, Luca
Ciccarese, Chiara
Rocca, Maria Cossu
Cianci, Claudia
Bimbatti, Davide
Aurilio, Gaetano
Antonuzzo, Andrea
Fantinel, Emanuela
Cullura, Daniela
Ricci, Sergio
Modena, Alessandra
Falcone, Alfredo
Tortora, Giampaolo
Nole, Franco
机构：
[1] European Inst Oncol, Med Oncol Div Urogenital & Head & Neck Tumors, Milan, Italy
[2] Univ Hosp Pisa, Oncol Unit 2, Pisa, Italy
[3] Univ Verona, Azienda Osped Univ Integrata, Med Oncol, I-37100 Verona, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 02期
关键词：
D O I：
10.1200/jco.2016.34.2_suppl.553
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
553
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Utility values among patients (pts) with metastatic renal cell carcinoma (mRCC) receiving first-line treatment with pazopanib (PZ) and sunitinib (SU).
    Hagiwara, May
    Park, Jinhee
    Delea, Thomas E.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] Prognostic factors for overall survival with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC)
    Patil, S.
    Figlin, R. A.
    Hutson, T. E.
    Michaelson, M. D.
    Negrier, S.
    Kim, S. T.
    Huang, X.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [3] Real world outcomes of patients with metastatic renal cell carcinoma (mRCC) using first-line sunitinib or pazopanib: the Canadian experience
    Lalani, A-K.
    Li, H.
    Heng, D.
    Wood, L.
    Kalirai, A.
    Bjarnason, G.
    Sim, H-W.
    Kollmannsberger, C. K.
    Kapoor, A.
    Hotte, S. J.
    Vanhuyse, M.
    Czaykowski, P.
    Reaume, M. N.
    Soulieres, D.
    Venner, P.
    North, S.
    Basappa, N.
    ANNALS OF ONCOLOGY, 2016, 27
  • [4] First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience
    Lalani, Aly-Khan A.
    Li, Haocheng
    Heng, Daniel Y. C.
    Wood, Lori
    Kalirai, Austin
    Bjarnason, Georg A.
    Sim, Hao-Wen
    Kollmannsberger, Christian K.
    Kapoor, Anil
    Hotte, Sebastien J.
    Vanhuyse, Marie
    Czaykowski, Piotr
    Reaume, M. Neil
    Soulieres, Denis
    Venner, Peter
    North, Scott
    Basappa, Naveen S.
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2017, 11 (3-4): : 112 - 117
  • [5] First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
    Morales, Jose Manuel Ruiz
    Wells, J. Connor
    Donskov, Frede
    Bjarnason, Georg A.
    Lee, Jae-Lyun
    Knox, Jennifer J.
    Beuselinck, Benoit
    Vaishampayan, Ulka N.
    Brugarolas, James
    Broom, Reuben James
    Bamias, Aristotelis
    Yuasa, Takeshi
    Srinivas, Sandhya
    Ernst, D. Scott
    Pezaro, Carmel Jo
    Wood, Lori
    Kollmannsberger, Christian K.
    Rini, Brian I.
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [6] First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the international metastatic renal cell carcinoma database consortium (IMDC).
    Morales, Jose Manuel Ruiz
    Swierkowski, Marcin
    Wells, Connor
    Fraccon, Anna Paola
    La Russa, Francesca
    Donskov, Frede
    Bjarnason, Georg A.
    Lee, Jae-Lyun
    Sim, Hao-Wen
    Beuselinck, Benoit
    Wood, Lori
    Yuasa, Takeshi
    Pezaro, Carmel Jo
    Rini, Brian I.
    Szczylik, Cezary
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] COST-UTILITY ANALYSIS OF PAZOPANIB VERSUS SUNITINIB AS FIRST-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC) IN SPAIN
    Espinosa, J.
    Gonzalez-Larriba, J. L.
    Maroto, P.
    Mendez-Vidal, M. J.
    Diaz-Cerezo, S.
    VALUE IN HEALTH, 2014, 17 (07) : A632 - A633
  • [8] A personalized sunitinib (S) first-line approach in elderly patients with metastatic renal cell carcinoma (mRCC).
    Rocca, Maria Cossu
    Iacovelli, Roberto
    Verri, Elena
    Crescio, Claudia
    Aurilio, Gaetano
    Detti, Serena
    Cullura, Daniela
    Nole, Franco
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [9] Impact of Concomitant Cardiovascular Medication on Survival of Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib or Pazopanib in the First Line
    Ondřej Fiala
    Pavel Ostašov
    Aneta Rozsypalová
    Milan Hora
    Ondřej Šorejs
    Jan Šustr
    Barbora Bendová
    Ivan Trávníček
    Jan Filipovský
    Jindřich Fínek
    Tomáš Büchler
    Targeted Oncology, 2021, 16 : 643 - 652
  • [10] Impact of Concomitant Cardiovascular Medication on Survival of Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib or Pazopanib in the First Line
    Fiala, Ondrej
    Ostasov, Pavel
    Rozsypalova, Aneta
    Hora, Milan
    Sorejs, Ondrej
    Sustr, Jan
    Bendova, Barbora
    Travnicek, Ivan
    Filipovsky, Jan
    Finek, Jindrich
    Buchler, Tomas
    TARGETED ONCOLOGY, 2021, 16 (05) : 643 - 652
12345